Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × Thyroxine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Postoperative Complications 1 Neoplasms 1 Hypothyroidism 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Ciprofloxacin 2 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1 pertuzumab 1 pembrolizumab 1 osimertinib 1 netupitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡